



# Identification of PGN\_1123 as the Gene Encoding Lipid A Deacylase, an Enzyme Required for Toll-Like Receptor 4 Evasion, in *Porphyromonas gingivalis*

Sumita Jain,<sup>a</sup> Ana M. Chang,<sup>a</sup> Manjot Singh,<sup>a</sup> Jeffrey S. McLean,<sup>a</sup> Stephen R. Coats,<sup>a</sup> Roger W. Kramer,<sup>b</sup> Richard P. Darveau<sup>a</sup>

<sup>a</sup>Department of Periodontics, School of Dentistry, University of Washington, Seattle, Washington, USA

<sup>b</sup>Institute of Systems Biology, Seattle, Washington, USA

**ABSTRACT** Removal of one acyl chain from bacterial lipid A by deacylase activity is a mechanism used by many pathogenic bacteria to evade the host's Toll-like receptor 4 (TLR4)-mediated innate immune response. In *Porphyromonas gingivalis*, a periodontal pathogen, lipid A deacylase activity converts a majority of the initially synthesized penta-acylated lipid A, a TLR4 agonist, to tetra-acylated structures, which effectively evade TLR4 sensing by being either inert or antagonistic at TLR4. In this paper, we report successful identification of the gene that encodes the *P. gingivalis* lipid A deacylase enzyme. This gene, PGN\_1123 in *P. gingivalis* 33277, is highly conserved within *P. gingivalis*, and putative orthologs are phylogenetically restricted to the *Bacteroidetes* phylum. Lipid A of  $\Delta$ PGN\_1123 mutants is penta-acylated and devoid of tetra-acylated structures, and the mutant strain provokes a strong TLR4-mediated proinflammatory response, in contrast to the negligible response elicited by wild-type *P. gingivalis*. Heterologous expression of PGN\_1123 in *Bacteroides thetaiotaomicron* promoted lipid A deacylation, confirming that PGN\_1123 encodes the lipid A deacylase enzyme.

**IMPORTANCE** Periodontitis, commonly referred to as gum disease, is a chronic inflammatory condition that affects a large proportion of the population. *Porphyromonas gingivalis* is a bacterium closely associated with periodontitis, although how and if it is a cause for the disease are not known. It has a formidable capacity to dampen the host's innate immune response, enabling its persistence in diseased sites and triggering microbial dysbiosis in animal models of infection. *P. gingivalis* is particularly adept at evading the host's TLR4-mediated innate immune response by modifying the structure of lipid A, the TLR4 ligand. In this paper, we report identification of the gene encoding lipid A deacylase, a key enzyme that modifies lipid A to TLR4-evasive structures.

**KEYWORDS** *Porphyromonas gingivalis*, TLR4, deacylase, immune evasion, lipid A, transposon

*Porphyromonas gingivalis* is an anaerobic Gram-negative bacterium found in subgingival plaque. It is closely associated with periodontitis, a chronic inflammatory disorder responsible for major tooth loss worldwide (1). *P. gingivalis* is found in higher abundance in diseased periodontal pockets than in healthy pockets (2, 3), indicating that it is adept at withstanding hostile immune conditions characteristic of periodontal diseased sites. The bacterium has been shown to express multiple virulence factors that enable it to evade, actively suppress, and modulate the host innate immune response (4–13), giving it the ability to persist under inflammatory conditions and to become a recurrent member of the bacterial community during disease. Furthermore, *P. gingivalis* infections in mouse and rabbit models have shown it to alter the composition of the subgingival microbiome and augment the bacterial load, marking it as a keystone

**Citation** Jain S, Chang AM, Singh M, McLean JS, Coats SR, Kramer RW, Darveau RP. 2019. Identification of PGN\_1123 as the gene encoding lipid A deacylase, an enzyme required for Toll-like receptor 4 evasion, in *Porphyromonas gingivalis*. *J Bacteriol* 201:e00683-18. <https://doi.org/10.1128/JB.00683-18>.

**Editor** Victor J. DiRita, Michigan State University

**Copyright** © 2019 American Society for Microbiology. All Rights Reserved.

Address correspondence to Sumita Jain, [sumita@uw.edu](mailto:sumita@uw.edu).


For a commentary on this article, see <https://doi.org/10.1128/JB.00146-19>.

**Received** 6 November 2018

**Accepted** 12 February 2019

**Accepted manuscript posted online** 19 February 2019

**Published** 8 May 2019



**FIG 1** Modification of the *P. gingivalis* lipid A structure. Penta-acylated bisphosphorylated lipid A (left), a moderate TLR4 agonist, is the initial lipid A structure synthesized by *P. gingivalis*. It is modified to tetra-acylated nonphosphorylated lipid A (right), which is silent for TLR4 activation, by the action of C-1- and C-4'-phosphatases and a 3'-O-deacylase. Inhibition of C-1-phosphatase activity leads to the formation of C-1-phosphorylated tetra-acylated lipid A, a TLR4 antagonist.

pathogen (14–17) with the capacity to trigger microbial dysbiosis. A consequence of dysbiosis, commonly seen in chronic inflammatory disorders, is breakdown of the homeostatic bacterial host balance, leading to aggravated immune responses that, in the case of periodontitis, manifest in loss of supporting structures of the tooth.

*P. gingivalis* is unusually adept at evading the innate immune response mediated by Toll-like receptor 4 (TLR4) (1, 18, 19), a major bacterial clearance mechanism mounted by the host. TLR4 is a host innate immune receptor that, together with its coreceptor myeloid differentiation factor 2 (MD-2), recognizes lipopolysaccharide (LPS), an essential macromolecule that forms the outer layer of the outer membrane in Gram-negative bacteria (20–23). The TLR4 ligand specifically is lipid A, a hydrophobic glycolipid anchor of LPS. Lipid A satisfies the requirements first outlined by Medzhitov and Janeway for pattern recognition receptor ligands in that the structure is highly conserved, is essential for bacterial survival, and differs significantly from host (self) structures (24). Engagement of bacterial lipid A by the TLR4/MD-2 complex initiates a proinflammatory response, which in turn leads to production of costimulatory molecules required for adaptive immunity, culminating in clearance of local infection. The prototypical lipid A structure, first investigated in *Escherichia coli*, comprises a disaccharide,  $\beta$ -1',6-glucosamine, to which is attached six C<sub>12</sub> to C<sub>14</sub> fatty acyl chains and two phosphate groups at the C-1 and C-4' positions (25). *E. coli* lipid A is highly immunostimulatory, being capable of triggering endotoxic shock even when encountered in small quantities in the bloodstream.

In striking contrast, *P. gingivalis* lipid A is a poor activator of TLR4 (26–28). The bacterium exhibits a heterogeneous population of lipid A structures comprising penta- and tetra-acylated molecules that are bis-, mono-, or nonphosphorylated. The initial structure synthesized is penta-acylated and bisphosphorylated with C<sub>15</sub> to C<sub>17</sub> acyl chain lengths (Fig. 1) and is a moderate TLR4 agonist (29). Under standard growth conditions, it is subject to the action of three lipid A-modifying enzymes leading to a lipid A profile that is heavily biased toward a tetra-acylated, nonphosphorylated structure (29). The three distinct enzymatic activities that modify *P. gingivalis* lipid A are C-1-phosphatase, C-4'-phosphatase, and 3'-O-deacylase (Fig. 1). When *P. gingivalis* is grown under conditions with high hemin, hemin being an iron source required for growth, the C-1-phosphatase is inactive, leading to a shift of tetra-acylated nonphosphorylated lipid A to tetra-acylated C-1-phosphorylated lipid A (30). Notably, both tetra-acylated structures are TLR4 evasive at the TLR4/MD-2 receptor complex. Non-phosphorylated tetra-acylated lipid A is inert for TLR4 activation, whereas C-1-phosphorylated tetra-acylated lipid A is an antagonist of TLR4 activation (29, 31). Our group was the first to describe TLR4 antagonism by *P. gingivalis* lipid A *in vitro*, and we have been investigating the mechanistic process as well as clinical implications. An-

tagonism of TLR4 has the potential to have a community-wide effect, since it can dampen the host response to any Gram-negative member of the oral community. The two tetra-acylated structures are, in short, key to the ability of *P. gingivalis* to effectively evade the host TLR4 immune attack.


The C-1- and C-4'-phosphatases were identified by our group, by homology searches, to be encoded by PG1773 and PG1587, respectively (W83 designations) (29). Recently, PG0027 was identified to possess C-1-phosphatase activity as well (32). Deletion of the C-1-phosphatase, PG1773, led to accumulation of C-1-phosphorylated, tetra-acylated lipid A, the TLR4 antagonist. Deletion of the C-4'-phosphatase, PG1587, on the other hand, resulted in formation of C-4'-phosphorylated lipid A, but it was exclusively penta-acylated, suggesting that the C-4'-phosphate moiety needs to be removed for lipid A deacylation to occur. The contribution of lipid A deacylation to attenuation of TLR4-dependent proinflammatory responses, and for facilitating *P. gingivalis* persistence, has been experimentally demonstrated *in vivo* in a murine model of infection comparing wild-type (WT) versus  $\Delta$ PG1587 mutant strains (33).

The gene encoding the lipid A deacylase, which is essential for the ability of *P. gingivalis* to evade TLR4 sensing, has, however, remained unidentified. Two known bacterial lipid A deacylase-encoding genes are *pagL* and *lpxR*, both of which were identified first in *Salmonella enterica* serovar Typhimurium (34, 35). These two deacylases are distinct from each other both in their primary sequence and in their modes of action, hydrolyzing a C-3 chain and C-3' acyloxyacyl pair of acyl chains, respectively. A comprehensive search for homologs of *pagL* and *lpxR* by us and other groups failed to identify the lipid A deacylase gene in *P. gingivalis* (34–36). *pagL* and *lpxR* have orthologs in other bacteria, but, interestingly, are all restricted to the *Proteobacteria* phylum. *P. gingivalis* PG0027 was earlier reported to carry the lipid A deacylase gene (37). This possibility, however, was ruled out both by personal communications with the author, Eric Reynolds, and by the recent finding that PG0027 participates in lipid A C-1-phosphatase activity (32) and has no effect on deacylase function.

In this report, we demonstrate that the lipid A deacylase in *P. gingivalis* 33277 is encoded by PGN\_1123. Identification of the gene began with a screen of a transposon mutant library, employing a functional assay developed for identifying novel mutants that elicit a strong host innate immune response. Using this approach, we identified a candidate mutant that demonstrated potent TLR4 activation, consistent with a lipid A deacylase phenotype. An affected gene in the transposon mutant was shown to be required for lipid A deacylation and identified to be PGN\_1123. The encoded protein is highly conserved in *P. gingivalis*, bearing no significant homology to the two known lipid A deacylases or to other proteins of known function, indicating that PGN\_1123 encodes a novel bacterial lipid A deacylase enzyme.

## RESULTS

**Development of a cell-based functional screen to identify *P. gingivalis* mutants that stimulate the human innate immune response.** Our goal was to identify novel genetic determinants that play a role in conferring to *P. gingivalis* its wide-ranging ability to evade immune recognition. We took the approach of screening a *P. gingivalis* mutant library for mutants that stimulate a high immune response. Monomac 6 (MM6) cells, a human monocyte cell line, were tested to serve as an *in vitro* model. Infection of MM6 cells with wild-type *P. gingivalis* 33277 did not induce secretion of the proinflammatory cytokine interleukin-6 (IL-6) in the supernatant, as measured by enzyme-linked immunosorbent assay (ELISA) (Fig. 2A). This is consistent with observations by us and others regarding the ability of *P. gingivalis* to effectively evade or dampen immune defense mechanisms (38–40). Infection with a 33277  $\Delta$ PG1587 mutant, which possesses TLR4-stimulating penta-acylated lipid A in its LPS, on the other hand, stimulated IL-6 secretion. This was in contrast to infection with a  $\Delta$ PG1773 mutant, which harbors anti-inflammatory tetra-acylated antagonistic lipid A. The gingipain proteases Kgp and Rgp are also known to dampen innate immune responses by, for example, degrading CD14 (41, 42), a coreceptor of TLR2 and TLR4 signaling




**FIG 2** The J5-c5 transposon mutant induces a proinflammatory response. The amounts of IL-6 secreted by MM6 cells in response to exposure to  $10^6$  or  $10^7$  intact *P. gingivalis* 33277 bacteria versus the isogenic  $\Delta$ PG1587,  $\Delta$ PG1773, or  $\Delta$ kgp mutant (A) and the J5-c5 transposon mutant (B and C) are shown. The results are means  $\pm$  standard deviations (SD) for triplicate samples from either one of two independent experiments (A) or from two separate experiments (B and C). Asterisks denote significant differences in amount of IL-6 secreted relative to that for the wild-type 33277 control ( $P < 0.01$  by 2-tailed unpaired *t* tests).

complexes. Infection of MM6 cells with a 33277  $\Delta$ kgp mutant indeed led to a higher IL-6 response. The MM6/IL-6 assay hence was validated as a sensitive model system for detecting increased immune-stimulatory activity by *P. gingivalis* mutants that is conferred by functional loss of an immune-modulating gene.

**Isolation of a *P. gingivalis* transposon mutant that stimulates a vigorous proinflammatory response.** We used a mariner transposon (Tn) isolated from *Bacteroides thetaiotaomicron*, a close relative of *P. gingivalis*, to create a *P. gingivalis* 33277 mutant library (43). Each round of mutagenesis yielded hundreds of mutants, obtained by selecting for erythromycin resistance conferred by the Tn-encoded erythromycin resistance cassette *ermG*. The Tn mutants were grown individually in 96-well plates for 2 days, at which point most had grown to visibly high turbidity. MM6 cells, also grown in 96-well plates, were infected with the mutant library and screened for IL-6 secretion by ELISA. The vast majority of  $\sim 1,000$  mutants screened exhibited nondetectable levels of IL-6 in the supernatant, similar to the case for the wild-type (WT) strain. A few mutants,  $\sim 5$  to 10%, exhibited a pronounced IL-6 response. A vast majority of the “positive-hit” mutants, however, were slow-growing strains, as was apparent by sight in the 96-well Tn mutant-holding plate. We speculated that slow-growing mutants were stimulating an increased inflammatory response due to low levels of expression of immune-suppressing proteases such as Kgp on the bacterial surface. We rescreened the putative positive-hit mutants and obtained one candidate, named J5-c5, which (i) displayed normal growth, similar to that of the WT, and (ii) stimulated IL-6 production, unlike the WT (Fig. 2B). These two features are characteristic phenotypes of  $\Delta$ PG1587 and  $\Delta$ kgp mutants as well.

**The J5-c5 mutant stimulates TLR4-dependent signaling and fails to produce tetra-acylated lipid A.** We investigated whether the proinflammatory response triggered by the J5-c5 Tn mutant was mediated by activation of either TLR2 or TLR4 innate immune receptors by utilizing a HEK293 luciferase reporter assay (44). Nonimmune HEK293 cells were transfected with either TLR2- or TLR4-expressing plasmids, followed by infection with wild-type 33277, J5-c5, or  $\Delta$ PG1587 intact bacterial cells. As seen in Fig. 3A, J5-c5 stimulated TLR4 strongly relative to 33277, similar to  $\Delta$ PG1587 mutants, but did not increase levels of TLR2 stimulation (Fig. 3B). Since this assay measures fold change in activation, TLR4 activation by J5-c5 is highly significant.

The ability to stimulate TLR4 suggested that the lipid A structure in J5-c5 is different from that of the wild type, which was confirmed by subjecting purified LPS to a TLR4 assay. LPS from J5-c5, similar to LPS from  $\Delta$ PG1587 mutants, stimulated TLR4 strongly relative to WT 33277 LPS (Fig. 3C), suggesting that the J5-c5 lipid A acylation status is



**FIG 3** J5-c5 mutants stimulate TLR4 but not TLR2. (A and B) HEK293 cells expressing TLR4/MD-2 (A) or TLR2/mCD14 (B) were infected with wild-type 33277,  $\Delta$ PG1587, or J5-c5 intact bacterial cells. (C) HEK293 cells expressing TLR4/MD-2 were exposed to LPS isolated from the wild type,  $\Delta$ PG1587, or the J5-c5 transposon mutant. Fold NF- $\kappa$ B stimulation of infected cells relative to the unstimulated control is plotted on the y axis. The results are means  $\pm$  SD for triplicate samples from one of two independent experiments. Asterisks denote a significant increase in fold NF- $\kappa$ B stimulation relative to that for the wild-type 33277 control ( $P < 0.05$  by 2-tailed unpaired *t* tests).


shifted to a more penta-acylated profile. We ruled out the possibility that the PG1587 gene, whose C-4'-phosphatase activity was shown by us to be required for lipid A deacylation, is affected in J5-c5 by assaying for polymyxin B sensitivity. A characteristic feature of  $\Delta$ PG1587 mutants is sensitivity to the cationic antimicrobial peptide polymyxin B, because of its penta-acylated lipid A being C-4'-phosphorylated (29). J5-c5 mutants, however, displayed polymyxin B resistance, similar to that of the wild-type bacterium, indicating that the PG1587 gene and the C-4'-phosphatase activity it encodes are intact in J5-c5.

We determined the J5-c5 mutant lipid A structure by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (MS). As seen in Fig. 4B, lipid A of the J5-c5 mutant displayed predominantly penta-acylated nonphosphorylated lipid A when viewed in positive-ion mode. This profile was strikingly different from that of the wild type, which displayed predominantly tetra-acylated nonphosphorylated lipid A (Fig. 4A). Tetra-acylated lipid A was abrogated to an undetectable level in J5-c5, indicating that deacylase function is absent or severely compromised.

The lipid A structure was also examined after growth of WT 33277 and the J5-c5 mutant under high-hemin conditions, a growth condition that abrogates C-1-phosphatase activity (30). In the WT, growth in high hemin leads to significant accumulation of antagonistic tetra-acylated C-1-phosphorylated lipid A, as can be viewed in negative-ion mode MALDI-TOF MS (Fig. 4C). This structure, however, was not detected in the largely penta-acylated J5-c5 lipid A profile (Fig. 4D), further confirming that deacylase function is severely compromised in this mutant.

Interestingly, we detected non-, mono-, and bisphosphorylated forms of penta-acylated lipid A in the J5-c5 mutant (Fig. 4B and D). The nonphosphorylated aspect accounts for resistance of J5-c5 to polymyxin B, while the penta-acylated feature accounts for high TLR4 stimulation. Nonphosphorylated penta-acylated lipid A is rarely observed in *P. gingivalis* 33277, but its production in J5-c5 indicates that both C-1- and C-4'-phosphatases are active, further validating that PG1587 C-4'-phosphatase has not been affected in J5-c5 and hence indicating disruption of a novel gene.

**The J5-c5 mutant contains multiple transposon insertions.** Semirandom and nested PCR was used to identify the location of the transposon (Tn) insertion in J5-c5. An insertion was found to be located in an intergenic location, 122 bp downstream of PGN\_0782 and 609 bp upstream of PGN\_0783. Transposons, however, are capable of jumping to new locations until the replication-incompetent plasmid, which encodes both transposon and transposase, is lost from the population. A precise swap of the transposon with *tetQ*, a tetracycline resistance cassette, did not eliminate erythromycin



**FIG 4** Lipid A of the *J5-c5* mutant is predominantly penta-acylated. MALDI-TOF mass spectrometry of the lipid A structure was conducted in positive-ion (A and B) and negative-ion (C and D) modes, which detect nonphosphorylated and phosphorylated structures, respectively. Tetra-acylated nonphosphorylated lipid A is seen in wild-type 33277 (A) but not in the *J5-c5* mutant (B), which instead exhibits penta-acylated nonphosphorylated lipid A. With growth under high-hemin conditions, tetra-acylated monophosphorylated antagonist is detected in the wild type (C) but not in the *J5-c5* mutant (D), which instead displays penta-acylated lipid A that is either mono- or bisphosphorylated ( $m/z$  1,769). Tetra-acylated lipid A is not detected under either condition in the *J5-c5* mutant. Numbers refer to the  $m/z$  ratio of the predominant peak in each lipid A cluster.

resistance, indicating the presence of additional transposons in *J5-c5*, which was confirmed by PCR (data not shown).

We sequenced the entire *J5-c5* genome on Illumina's MiSeq platform to determine the number and locations of transposons in *J5-c5*. Analysis of the *J5-c5* sequencing reads revealed approximately  $5\times$  coverage of Tn sequence relative to the 33277 RefSeq chromosomal sequence, suggesting the presence of five transposons in *J5-c5*. The insertion site of one of them, Tn-1, precisely matched the location identified by the PCR-based methods described above. The locations of the four other transposons are listed in Table 1.

**PGN\_1123 encodes the lipid A deacylase.** Since it was not clear which one or combination of Tn insertions was responsible for the deacylase phenotype or, indeed, whether the phenotype was due to direct interruption of a deacylase gene or due to

**TABLE 1** Locations of the five transposon insertions in *J5-c5*

Name	Chromosomal position in strain 33277	Genetic location; protein
Tn1	854777	Intergenic, 609 bp upstream of PGN_0783; histone-like DNA binding protein
Tn2	62040	Intergenic, 52 bp upstream of PGN_0053; hypothetical protein, 408 aa
Tn3	85364	In PGN_0081; <i>matE</i> family efflux transporter
Tn4	1252900	In PGN_1124; Band 7 protein, 326 aa
Tn5	1653844	Intergenic, 523 bp upstream of PGN_1476; T9SS C-terminal target domain-containing protein

**TABLE 2** Top 20 most significant changes in gene expression between the wild-type and J5-c5 transposon mutant strains as revealed by edgeR analysis

Name	Product	Log <sub>2</sub> fold change	P value
PGN_1123	Hypothetical protein	-4.71590586	3.66E-06
PGN_1281	Conjugative transposon protein TraM	-2.276704451	0.000305862
PGN_0783	DNA binding protein	-7.281703828	0.00035261
PGN_0090	DNA binding protein	-2.304121237	0.000717639
PGN_0066	Transposase	-2.142286175	0.000941805
PGN_0060	Conjugative transposon protein TraM	-2.198185031	0.000882388
PGN_1124	Paraslipin	-1.690660121	0.001456315
PGN_0084	DNA topoisomerase I	-1.699090077	0.001497081
PGN_0083	Hypothetical protein	-1.703911427	0.001862623
PGN_0065	Transposase	-1.954910211	0.001886738
PGN_1283	Conjugal transfer protein TraO	-1.856001435	0.002120805
PGN_0784	Hypothetical protein	-5.588007472	0.002152355
PGN_0061	Transposase	-2.4521437	0.002448023
PGN_0064	Transposase	-1.800519514	0.002979058
PGN_1282	Conjugative transposon protein TraN	-1.636844785	0.003527579
PGN_0063	Conjugative transposon protein TraJ	-1.868293938	0.004728484
PGN_0194	Hypothetical protein	3.227338786	0.004526265
PGN_0074	Hypothetical protein	-2.247462691	0.007013359
PGN_0901	6,7-Dimethyl-8-ribityllumazine synthase	2.462105689	0.00738567
PGN_0067	Transposase	-1.732652686	0.008098611


an indirect effect via gene regulation, we employed transcriptome sequencing (RNA-seq) to determine the genes that are differentially expressed between wild-type 33277 and the J5-c5 mutant. The top 20 genes displaying the most significant changes in log<sub>2</sub> expression values in J5-c5 mutant relative to the wild type, as determined by utilizing edgeR with the default parameters described by Law et al. (45), are listed in Table 2. The statistical parameters of this package identified exactly one gene, PGN\_1123, as significantly differentially expressed. PGN\_1123 is located immediately downstream of the gene interrupted by Tn4, PGN\_1124. Besides PGN\_1123, the only genes that displayed >4-fold decreases in log<sub>2</sub> expression values were located on one side of Tn1, i.e., PGN\_0783 and PGN\_784.

We targeted the PGN\_1123, PGN\_1124, and PGN\_0783 genes for deletion analysis in *P. gingivalis* 33277. Deletion mutations were constructed by replacing each gene with a nonpolar erythromycin resistance cassette, *ermF*, using homologous recombination.

The deletion mutation in PGN\_1123 was found to confer the lipid A deacylase phenotype, as demonstrated by structural and functional analyses. Lipid A of the ΔPGN\_1123 mutant was devoid of tetra-acylated structures, and the mutant displayed predominantly penta-acylated nonphosphorylated lipid A (Fig. 5A), similar to the case for the J5-c5 Tn mutant, as determined by MALDI-TOF MS. On the other hand, both the ΔPGN\_1124::*ermF* and ΔPGN\_0783::*ermF* mutants displayed the wild-type tetra-acylated phenotype as seen in Fig. 4A (data not shown).

We were successful in complementing the ΔPGN\_1123::*ermF* deacylase phenotype by introducing a plasmid expressing PGN\_1123 in *trans*. The PGN\_1123 gene was cloned into pSJ46, a pT-COW-based plasmid vector capable of replicating in both *E. coli* and *P. gingivalis*, generating the plasmid pSJ836. Conjugation was used to mobilize pSJ836 from *E. coli* to ΔPGN\_1123::*ermF* mutants, and expression of the PGN\_1123 gene was confirmed by reverse transcription-PCR (RT-PCR) (data not shown). Analysis of ΔPGN\_1123::*ermF* (pSJ836) lipid A demonstrated the presence of tetra-acylated nonphosphorylated structures, similar to the case for the wild type (Fig. 5B). Complementation of the ΔPGN\_1123::*ermF* penta-acylated lipid A phenotype to tetra-acylated lipid A in ΔPGN\_1123(pSJ836) confirmed that PGN\_1123 is required for lipid A deacylation.

Consistent with an absence of tetra-acylated lipid A, infection of TLR4-expressing HEK293 cells with ΔPGN\_1123::*ermF* mutant whole cells induced potent TLR4 stimulation (Fig. 6), similar to the case for J5-c5. ΔPGN\_1124 mutants, on the other hand, displayed a nonactivating phenotype similar to that of the wild type, indicating that the




**FIG 5** The  $\Delta$ PGN<sub>1123</sub> mutant is devoid of tetra-acylated lipid A. (A) Lipid A preparations of  $\Delta$ PGN<sub>1123</sub>::*ermF* mutants exhibit penta-acylated nonphosphorylated lipid A as detected by MALDI-TOF MS in positive-ion mode and a distinct absence of tetra-acylated lipid A. (B)  $\Delta$ PGN<sub>1123</sub> mutants expressing the PGN<sub>1123</sub> gene in *trans* from pSJ836 display tetra-acylated nonphosphorylated lipid A, similar to that of the wild type, indicating complementation of lipid A deacylase function. Numbers refer to the *m/z* ratio of the predominant peak in each lipid A cluster.

gene interrupted by the Tn responsible for the deacylase phenotype due to polar effects on PGN<sub>1123</sub> itself does not play a role in TLR4 evasion. Introduction of pSJ836, the plasmid expressing PGN<sub>1123</sub>, into  $\Delta$ PGN<sub>1123</sub> mutants resulted in a substantial reduction of TLR4 stimulation, confirming complementation of the lipid A deacylase phenotype.


Furthermore, replacement of Tn<sub>4</sub> alone, out of the five Tns present in J5-c5, with a nonpolar tetracycline resistance cassette also restored lipid A deacylase activity (data not shown), confirming that Tn<sub>4</sub> was the sole Tn in J5-c5 responsible for conferring the lipid A deacylase phenotype, specifically by exerting polar effects on downstream gene transcription.

**PGN<sub>1123</sub> encodes a novel phylogenetically restricted deacylase and is part of an operon.** PGN<sub>1123</sub> is annotated to encode a conserved hypothetical protein comprising 399 amino acid residues. Homology searches did not reveal any obvious similarity to a protein of known function, and the protein does not display known motifs. PGN<sub>1123</sub> is highly conserved in *P. gingivalis*, with homologs displaying 92 to



**FIG 6**  $\Delta$ PGN<sub>1123</sub>::*ermF* mutants stimulate TLR4. HEK293 cells expressing TLR4/MD-2 were stimulated with wild-type 33277, J5-c5 transposon mutant, or isogenic  $\Delta$ PGN<sub>1124</sub>,  $\Delta$ PGN<sub>1123</sub>, or  $\Delta$ PGN<sub>1123</sub>(pSJ836) whole bacterial cells. The last sample,  $\Delta$ PGN<sub>1123</sub> (pSJ836), expresses PGN<sub>1123</sub> from pSJ836 in *trans*. Fold NF- $\kappa$ B stimulation of infected cells relative to the unstimulated control is plotted on the y axis. The results are means  $\pm$  SD for triplicate samples from one of three independent experiments. Asterisks denote a significant increase in fold NF- $\kappa$ B stimulation relative to that for the wild-type 33277 control ( $P < 0.05$  by 2-tailed unpaired *t* tests).





**FIG 7** PGN\_1123 is in an operon with the upstream PGN\_1125 and PGN\_1124 genes. RT-PCR of mRNA from wild-type 33277 using primers a and b overlapping PGN\_1125 and PGN\_1124 (lane 2), primers c and d overlapping PGN\_1124 and PGN\_1123 (lane 4), and primers a and d overlapping PGN\_1125 PGN\_1123 (lane 6) is shown. Reverse transcriptase is absent in lanes 3, 5, and 7, which use the same primer sets as for lanes 2, 4, and 6, respectively. A molecular weight ladder is in lane 1.

98% identity present in all sequenced *P. gingivalis* strains. An ortholog with 92% identity was found in *Porphyromonas gulae*, after which identity to the next closest homolog fell to 43%, in *P. crevioricanis*. Orthologs with 30 to 35% identity were found in several bacteria, all belonging to the *Bacteroidetes* phylum, including *Prevotella stercorea* (35% identity), *Tannerella forsythia* (36% identity), *Parabacteroides goldsteinii* (35% identity), and *Bacteroides fragilis* (33% identity). Comparison of the PGN\_1123 protein sequence with those of the known deacylases PagL and LpxR revealed low identity (<15%). Since PagL and LpxR are not orthologs of each other either and exhibit differences in their modes of action, PGN\_1123 represents a third distinct class of bacterial lipid A deacylase enzymes.


Both PagL and LpxR have been shown to be outer membrane proteins with  $\beta$ -barrel structures (46, 47). Using several web-based tools, PGN\_1123 is predicted to have a signal sequence, required for secretion across the inner membrane in Gram-negative bacteria, with a potential cleavage site located after the 19th amino acid (aa). One of several tertiary structure predictions of PGN\_1123 using the I-TASSER server at the University of Michigan (48) revealed a  $\beta$ -barrel structure.

The start codon of the PGN\_1123 gene overlaps the stop codon of the gene upstream, PGN\_1124, suggesting that the two genes are translationally coupled. Indeed, it has been demonstrated that the homologs in *P. gingivalis* W83, PG1334 and PG1333, are cotranscribed together with the gene upstream, PG1335 (49), indicating that the three genes are organized in an operon. The first gene of the operon, PG1335 in W83, is 27 bp upstream of the second gene, PG1334. The three genes, PGN\_1125, PGN\_1124, and PGN\_1123 (PG1335, PG1334, and PG1333 in W83), are all conserved in sequenced *P. gingivalis* strains.

Interestingly, PG1334, the middle gene of the operon in W83, was identified in an *in vivo*-induced antigen technology (IVIAT) study as a gene that is induced *in vivo* during human periodontitis (50). Subsequent quantitative RT-PCR studies by Walters et al. confirmed that the PG1334 transcript is detected more frequently in dental plaque samples from periodontal disease sites than from healthy sites after taking into account *P. gingivalis* abundance, consistent with induction of expression during disease (49).

We conducted semiquantitative RT-PCR (Fig. 7) to confirm that the three genes are cotranscribed in 33277 as well. We detected mRNA overlapping the PGN\_1125 and PGN\_1124 genes, PGN\_1124 and PGN\_1123, and, importantly, PGN\_1125 and PGN\_1123, the first and last genes, demonstrating that they form an operon. This strongly suggests that PGN\_1123 is induced *in vivo* during disease.

**PGN\_1123 deacylates *Bacteroides thetaiotaomicron* lipid A.** In order to obtain definitive evidence that PGN\_1123 is a structural gene encoding the lipid A deacylase,



**FIG 8** *B. thetaiotaomicron* lipid A is deacylated by PGN\_1123. (A and B) Lipid A structure of *B. thetaiotaomicron* with empty plasmid vector pSJ46 (A) or PGN\_1123-expressing plasmid pSJ836 (B) as detected by MALDI-TOF MS in negative-ion mode. (C) HEK293 cells expressing TLR4/MD-2 were stimulated with *B. thetaiotaomicron*(pSJ46) or *B. thetaiotaomicron*(pSJ836) intact bacterial cells. Fold NF- $\kappa$ B stimulation of infected cells relative to an unstimulated control is plotted on the y axis. The results are means  $\pm$  SD for triplicate samples from one of two independent experiments. Asterisks denote a significant decrease in fold NF- $\kappa$ B stimulation relative to that for *B. thetaiotaomicron*(pSJ46) ( $P < 0.01$  by 2-tailed unpaired *t* tests).

we expressed PGN\_1123 heterologously in *B. thetaiotaomicron*, a phylogenetically close relative of *P. gingivalis*; both belong to the order *Bacteroidales* in the phylum *Bacteroidetes*. Lipid A from *B. thetaiotaomicron* is penta-acylated and C-1-phosphorylated (Fig. 8A, *m/z* 1,675), structurally similar to the penta-acylated, C-4'-phosphorylated lipid A cluster seen in *P. gingivalis*. To our knowledge, tetra-acylated lipid A has not been observed before in *B. thetaiotaomicron*, nor does the bacterium contain a PGN\_1123 homolog when searched with BLAST tools, which is in marked contrast to the case for *B. fragilis*. *B. thetaiotaomicron* LPS is a strong activator of TLR4 (stronger than *P. gingivalis* LPS) due to location of the phosphate group at the C-1 position instead of the C-4' position (51). Strong TLR4 activation by *B. thetaiotaomicron* LPS, and by whole bacteria, suggests that, unlike in *P. gingivalis*, there are no attenuating tetra-acylated lipid A structures capable of dampening TLR4 activation.

Consistent with PGN\_1123 encoding deacylase activity, *B. thetaiotaomicron* harboring pSJ836 in *trans* led to deacylation of penta-acylated monophosphorylated lipid A to tetra-acylated monophosphorylated lipid A (*m/z* 1,420), as revealed by MALDI-TOF MS in the negative-ion mode (Fig. 8B). This marks the first time we have observed tetra-acylated lipid A in *B. thetaiotaomicron*. A HEK293 TLR4 assay revealed that TLR4 activation by *B. thetaiotaomicron*(pSJ836) intact bacteria was substantially lower than that by *B. thetaiotaomicron* containing vector alone (Fig. 8C), providing novel evidence that expression of the PGN\_1123 gene product is sufficient to confer a TLR4-evasive phenotype in *B. thetaiotaomicron*. Lipid A deacylation in *B. thetaiotaomicron* by heterologous expression of PGN\_1123 confirms that PGN\_1123 encodes a lipid A deacylase.

## DISCUSSION

We report identification of PGN\_1123 as the lipid A deacylase-encoding gene in *P. gingivalis*, a gene that plays a pivotal role in evasion and suppression of the TLR4-mediated host innate immune response. Identification of this gene has been sought since TLR4 antagonism by tetra-acylated lipid A in *P. gingivalis* was first described, over 2 decades ago. The reason for the inability to identify this gene by homology searches is now clear, since PGN\_1123 does not display homology to the two known deacylases, PagL and LpxR. Additionally, the sequence of PGN\_1123 is unique in that it does not have close homologs outside *P. gingivalis* (with the exception of *P. gulae*), nor does it contain motifs that could inform us of its function. In this report, we have shown that PGN\_1123 is required for lipid A deacylation by structural and functional studies and have established that it encodes the lipid A deacylase enzyme by demonstrating deacylation following heterologous expression in *B. thetaiotaomicron*.

Lipid A is a fundamental component of the bacterial outer membrane. Remodeling of the membrane by lipid A deacylation has been shown to play a significant role in

pathogenesis in several bacteria on account of its moderating effect on the immune response. Lipid A deacylation in *B. thetaiotaomicron* as mediated by PGN\_1123 did indeed attenuate TLR4 activation, leading us to speculate on the reason for the absence of the genetic capability for deacylation in this intestinal commensal bacterium, which results in synthesis of a lipid A structure that is an unequivocal stimulator of TLR4. *B. fragilis*, belonging to the same genus and considered an opportunistic pathogen, on the other hand, possesses an ortholog of the PGN\_1123 protein, suggesting that it has the capacity to undergo lipid A deacylation. This bacterium, however, has not been shown to display deacylated lipid A when grown *in vitro*. Further studies are warranted to more fully understand the expression of putative deacylase genes in *Bacteroides* spp. Notably, PGN\_1123 belongs to a third distinct class of bacterial lipid A deacylase enzymes, and it remains feasible that there are other novel classes that remain unidentified.

Many pathogens possess the ability to disrupt TLR4 signaling by lipid A deacylation. *S. Typhimurium*, for example, undergoes *pagL*-dependent lipid A deacylation in response to low pH and low  $\text{Ca}^{2+}/\text{Mg}^{2+}$  concentrations, as would be encountered in phagolysosomes, suggesting that deacylation is important for pathogenesis (52). *Pseudomonas aeruginosa* lipid A was shown to undergo deacylation in isolates from cystic fibrosis patients by upregulation of *pagL* expression, which was not seen in environmental isolates (53). A striking example of deacylated lipid A contributing to pathogenesis is seen in *Yersinia pestis*, the etiologic agent of bubonic plague, which shuttles between a flea vector and humans. When incubated at 27°C, the environmental temperature of its flea vector, lipid A is composed of predominantly hexa-acylated lipid A structures, but when incubated at 37°C, the mammalian host temperature, a shift to a tetra-acylated form was observed (54, 55). The temperature-dependent shift in lipid A structure was shown to occur in *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* as well, and *lpxR* activity was demonstrated to remove the 3'-acyl-oxy-acyl chain in *Y. enterocolitica* (56). Tetra-acylated lipid A in *Y. pestis*, which is considered to occur due to decreased acyl transferase activity, rendered the bacterium silent to TLR4 recognition and reduced the inflammatory response, hence potentially allowing the pathogen to proliferate undetected in the bloodstream during early stages of infection. Interestingly, genetic modification of tetra-acylated lipid A to a hexa-acylated structure led to potent TLR4 stimulation but rendered the strain avirulent in a mouse model of infection (57), highlighting the important role of a reduced number of acyl chains in pathogenesis.

*P. gingivalis* is a unique member of the subgingival plaque microbial community in that it has the distinct capacity to foil TLR4 signaling, even antagonizing it, giving it the capacity to protect itself and, potentially, bystander bacteria in the plaque community as well. This is consistent with the observation that *P. gingivalis* is observed in high abundance in diseased plaque sites and is also associated with an increase in microbial load and an alteration in plaque microbial composition in animal models of infection. *P. gingivalis* hence has pathogenic properties that can be significantly attributed to TLR4 evasion by tetra-acylated lipid A. The phenotype of *P. gingivalis*  $\Delta$ PGN\_1123 mutants *in vivo* with respect to colonization, instigation of dysbiosis, and chronic inflammation remains to be tested. Mutants displaying penta-acylated lipid A due to deletion of the PG1587 gene were shown to stimulate a proinflammatory response and displayed reduced survival in a mouse macrophage model of infection (33).  $\Delta$ PG1587 mutants were shown to be defective for colonization in a rabbit model of infection as well (17), indicating that lipid A deacylation is required for pathogenesis. The distinction, if any, between the penta-acylated lipid A mutants, the  $\Delta$ PGN\_1123 and  $\Delta$ PG1587 mutants, which possess largely nonphosphorylated lipid A versus exclusively C-4'-phosphorylated lipid A, respectively, will become clear from future *in vivo* studies.

Expression of the PGN\_1123 gene is predicted to be upregulated during disease as inferred from upregulation of the cotranscribed PGN\_1124 gene during disease. Gene regulation has been reported for both *pagL* and *lpxR* deacylases, by several molecular mechanisms and in response to environmental conditions. *pagL* transcription in *S. Typhimurium*, for example, is activated by the two-component regulator PhoPQ in

response to different host microenvironments that include acidic pH, cationic antimicrobial peptides, and depletion of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  (34). Noncoding small RNA (sRNA) molecules are known to modulate expression of outer membrane proteins and have been shown to regulate both *pagL* and *lpxR*. MicF is an sRNA that binds to *lpxR* transcripts in *Salmonella*, increasing degradation of the mRNA by exposing regions that are susceptible to RNase E (58). A recent study identified an sRNA, Sr006, as a positive regulator of *pagL* expression in *P. aeruginosa*, leading to a reduction in the proinflammatory response (59). Another recent study in enterohemorrhagic *E. coli* (EHEC) identified two virulence regulators, Ler and Pch, as positive regulators of *lpxR* (60).

Increased expression of PGN\_1123 during disease would correlate with enhanced survival under inflammatory conditions. The cotranscribed PGN\_1124, shown to be expressed prominently during disease, has a motif indicating it belongs to the Band 7 family of proteins, a family conserved from protozoa to mammals. Also called the slipin (stomatatin-like integral membrane protein) family, it is implicated in regulating membrane protein turnover in stomatins and other membrane-associated proteins. It is often cotranscribed with a gene encoding a membrane protease, which in *P. gingivalis* is predicted to be encoded by PGN\_1125, the first gene of the operon. Genes in an operon often are part of the same functional pathway, but since a deletion mutation in PGN\_1124 did not affect lipid A deacylase function (Fig. 6) or structure (data not shown), the reason for these three genes to be in an operon is not clear. Interestingly, the transcript overlapping PGN\_1124 and PGN\_1123, the second and third genes of the operon, was more abundant than that overlapping the first two genes or all three genes (Fig. 7), indicating an additional level of transcriptional control for PGN\_1123 expression independent of the operon.

In addition to TLR4 evasion, it is becoming established that lipid A deacylation contributes to pathogenesis in bacteria by facilitating the formation of outer membrane vesicles (OMVs) (61–63). The presence of fewer acyl chains in the lipid A moiety leads to a reduction in the hydrophobic area of the molecule. The associated change in membrane structure, from a cone to either a cylinder or an inverted cone, has been proposed to facilitate increased membrane curvature, the first step toward outer membrane blebbing and OMV formation (64).

*P. gingivalis* is known to release a large number of OMVs, which may be a function of its largely tetra-acylated lipid A profile. OMVs from *P. gingivalis* mediate coaggregation with other bacteria and heme acquisition and, furthermore, are known to invade host epithelial tissue themselves with, as it turns out, a large arsenal of virulence proteins (62, 63). The proteomic and LPS contents of *P. gingivalis* OMVs have been shown to be different from those of the outer membrane by having (i) elevated levels of proteins secreted by the type IX secretion system (T9SS), which include gingipain proteases and other virulence factors, and (ii) an increased proportion of anionic A-LPS relative to neutral O-LPS (65, 66). Colocalization of type IX secreted proteins and A-LPS is consistent with the finding that T9SS proteins use A-LPS as an anchor for attachment to the outer membrane (67–69). Interestingly, many bacteria have been shown to pack a preferential cargo of proteins into their OMVs (70–75), suggesting that membrane remodeling occurs prior to, and may facilitate, vesiculation.

The lipid A content of *P. gingivalis* OMVs was also shown to be different from that of the outer membrane by being nearly devoid of penta-acylated lipid A structures and instead composed of tetra- and/or triacylated lipid A, leading the authors to conclude that lipid A in OMVs is more heavily deacylated than lipid A in outer membranes (32, 65). Interestingly, a recent study on an *S. Typhimurium* strain expressing recombinant *pagL* deacylase demonstrated lipid A deacylation from hexa- to penta-acylated structures as expected, but this, notably, led to increased vesiculation (61). Moreover, the deacylated (penta-acyl) lipid A was detected exclusively in OMVs and not in the bacterial outer membrane, suggesting that PagL-mediated changes in membrane structure contributed to membrane curvature and to formation of OMVs.

We recently reported in a collaborative study that nondeacylated (penta-acyl) lipid A from *P. gingivalis*  $\Delta$ PG1587 mutants is not only an agonist for TLR4 stimulation but

also an agonist of inflammasome activation (33), an immune pathway that targets intracellular cytosolic bacteria for elimination by pyroptosis. Bacterial lipid A has been shown to bind murine caspase-11 and its homolog in humans, caspase-4/5, resulting in inflammasome activation by the noncanonical pathway (76, 77). Underacylated lipid A, on the other hand, specifically tetra-acylated forms, was shown to bind caspases but failed to induce activation. Hence, lipid A structural modifications that abrogate TLR4 activation also abrogate inflammasome activation, as has been shown by us with *P. gingivalis* and by others in bacteria such as *Francisella novicida*.

In summary, lipid A deacylation has been shown to be involved in a wide range of functions that each contributes to pathogenesis. Identification of PGN\_1123 as the deacylase-encoding gene in *P. gingivalis* will now enable us to gain further insights into the precise role of deacylation in immune evasion and virulence factor expression and, furthermore, the potential contribution *in vivo* toward survival, dysbiosis, and chronic inflammation. Identification also lays the foundation for investigating the use of deacylase gene expression as a potential diagnostic tool, and inhibition of the enzyme as a potential therapeutic, for periodontitis.

## MATERIALS AND METHODS

**Bacterial strains and growth conditions.** *P. gingivalis* 33277, *Bacteroides thetaiotaomicron* ATCC 29148, and *E. coli* DH10b were obtained from our culture collection. *E. coli* SM10 $\lambda$ pir(pSAM\_Bt) was obtained from Andrew Goodman's laboratory (43). *P. gingivalis* strains were grown on blood agar plates containing 5% sheep's blood and in TYHK broth (30 g/liter Trypticase soy broth, 5 g/liter yeast extract, and 1 mg/liter vitamin K<sub>3</sub>). Following sterilization by autoclaving, filter-sterilized hemin was added to TYHK broth, just prior to inoculation, to a final concentration of 1  $\mu$ g/ml. Hemin was added at 10  $\mu$ g/ml for growth under high-hemin conditions. TYHK agar plates were used for growth of *P. gingivalis* on solid medium as well. Hemin (1  $\mu$ g/ml) and antibiotics were added following sterilization. Antibiotics were added to the following concentrations: erythromycin (Erm), 5  $\mu$ g/ml; tetracycline (Tet), 0.5  $\mu$ g/ml. *E. coli* strains were grown in Luria broth (10 g/liter tryptone, 5 g/liter yeast extract, 5 g/liter NaCl); 100  $\mu$ g/ml ampicillin was added when required for selection. *B. thetaiotaomicron* was grown on TYHK agar plates and in TYHK broth containing 1  $\mu$ g/ml hemin. All anaerobic strains were grown in an anaerobic growth chamber (5% H<sub>2</sub>, 5% CO<sub>2</sub>, 90% N<sub>2</sub>) at 37°C.

**Transposon mutagenesis.** Conjugation was used to transfer the mariner transposon-containing plasmid pSAM\_Bt from *E. coli* SM10 $\lambda$ pir to *P. gingivalis* 33277. pSAM\_Bt encodes the (i) RP4 origin of transfer, which is required for mobilization by biparental mating, (ii) the mariner transposon, encompassing an *ermG* cassette that confers erythromycin resistance, and (iii) the transposase encoding gene, which is required for transposition. *P. gingivalis* 33277 (100 ml) and SM10 $\lambda$ pir(pSAM\_Bt) (25 ml) were grown to mid-log phase to optical densities at 600 nm (OD<sub>600</sub>) of  $\sim$ 1.0 and  $\sim$ 0.5, respectively. After pelleting and resuspending each culture in 1 ml TYK broth, the two cultures were mixed, and 100- $\mu$ l aliquots were spotted on blood agar plates and incubated overnight aerobically. The bacterial mixes from 8 to 10 spots were transferred using sterile swabs into 10 ml phosphate-buffered saline (PBS), spun, and resuspended in 1.5 ml TYK broth. Aliquots (100  $\mu$ l) were plated on TYHK plates containing 5  $\mu$ g/ml erythromycin for selection of transposon-containing 33277 strains and containing 50  $\mu$ g/ml gentamicin for counterselection of *E. coli*. Transposon-containing erythromycin- and gentamicin-resistant 33277 colonies were seen after 4 to 5 days of anaerobic incubation.

Transposon mutant candidate colonies were patched on TYHK-Erm-Gm plates at 48 colonies per plate. After 3 to 4 days of growth, they were inoculated into 150  $\mu$ l TYHK-Erm medium in 96-well plates. Two days later, they were used for infection of MM6 cells.

**IL-6 production from MM6 cells.** Monomac 6 (MM6) cells were grown in medium comprising RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 1% penicillin-streptomycin, 1% nonessential amino acids, and 1% OPI medium supplement, and then  $2.5 \times 10^5$  cells were seeded in 96-well plates in 200- $\mu$ l aliquots. Twenty-four hours later, the cells were infected with 20  $\mu$ l of each Tn mutant that had been grown for 2 days in the 96-well holding plate. At 24 h after infection, the cells were spun down in the 96-well plate, and the amount of IL-6 in 100  $\mu$ l supernatant was measured by ELISA according to the manufacturer's instructions (eBioscience).

**Preparation of LPS and isolation of lipid A.** Bacteria were cultured for 48 h in TYHK medium containing 1  $\mu$ g/ml hemin or 10  $\mu$ g/ml hemin (for growth under high-hemin conditions). LPS was isolated from 150 ml of culture using the Tri-reagent protocol as previously described (44). To generate lipid A, dried LPS samples were resuspended in 10 mM sodium acetate (pH 4.5) containing 1% sodium dodecyl sulfate. The solution was heated for 1 h at 100°C, followed by lyophilization overnight. The resulting dried lipid A was resuspended in ice-cold 95% ethanol containing 0.02 N HCl, spun, washed three times in 95% ethanol, and subjected to a final extraction with 1,160  $\mu$ l of chloroform-methanol-water (1:1:0.9), a biphasic solution that separates residual carbohydrate contaminants into the aqueous phase. The chloroform layer containing the lipid A was dried in a fume hood and used for MALDI-TOF MS analyses.

**MALDI-TOF MS.** Lipid A samples were dissolved in 10  $\mu$ l norharmane matrix, which was prepared by adding 10 mg norharmane to 1 ml of a 1:1 chloroform-methanol solution and mixing well. One microliter

of each sample was analyzed in both positive- and negative-ion modes on an AutoFlex II Analyzer (Bruker Daltonics). Data were acquired with a 50-Hz repetition rate, and up to 3,000 shots were accumulated for each spectrum. Instrument calibration and all other tuning parameters were optimized using HP Calmix (Sigma-Aldrich). Data were acquired and processed using Flex Analysis software (Bruker Daltonics).

**HEK293 TLR2 and TLR4 assays.** The HEK293 TLR2 and TLR4 assays were performed as previously described (44). Briefly, HEK293 cells were plated in 96-well plates and transfected the following day with plasmids encoding human TLRs, NF- $\kappa$ B-dependent firefly luciferase reporter, and  $\beta$ -actin promoter-dependent *Renilla* luciferase reporter. In the case of human TLR4, 0.002  $\mu$ g plasmid encoding human TLR4 was cotransfected with 0.0025  $\mu$ g plasmid encoding human MD-2. In the case of human TLR2, 0.001  $\mu$ g plasmid encoding TLR2 was cotransfected with 0.002  $\mu$ g plasmid encoding human mCD14. At 18 to 20 h posttransfection, test wells were stimulated in triplicate for 4 h at 37°C with various doses of sample, which were suspended in Dulbecco's modified Eagle medium (DMEM) containing 10% human serum. For stimulation with intact bacteria, 1-ml cultures of the indicated strains were first washed with TYHK, and their concentration was estimated by measuring the optical density at 600 nm. Luciferase activity was assayed using a dual-luciferase assay reporter system (Promega, Madison, WI). NF- $\kappa$ B activity was measured as the ratio of NF- $\kappa$ B-dependent firefly luciferase activity to  $\beta$ -actin promoter-dependent *Renilla* luciferase activity, which served as an internal standard. The data were plotted as the fold difference between the NF- $\kappa$ B activity of the sample and that of the unstimulated control.

**Nested PCR to identify transposon insertion sites.** Semirandom primer Arb1 (78) was used with a primer reading outwards from the mariner transposon, SamSeq2 (43), to amplify the transposon-chromosome junction by PCR. Several fragments obtained were gel extracted together and used as the template for a nested PCR product using primers Arb2 (same as Arb1 but lacking the semirandom N nucleotides) and SamSeq2, a primer reading outwards and closer to the edge of the transposon than SamSeq1. A prominent 650-bp PCR product was obtained, which was cleaned and sent for Sanger sequencing at Genewiz.

**Whole-genome sequencing and analysis.** Genomic DNA was purified from *P. gingivalis* cultures using the DNeasy blood and tissue kit (Qiagen). Genomic DNAs from wild-type 33277 and the transposon mutant J5-c5 were subjected to paired-end, whole-genome sequencing on Illumina's MiSeq platform.

Transposon insertion sites in J5-c5 were identified by aligning reads spanning junction sites between the genomic sequence and the termini of the transposon. The reads were first trimmed and filtered based on quality analysis by FastQC. Next, they were aligned against the *P. gingivalis* 33277 reference genome using Bowtie2, and unalignable reads were aligned against the sequence of the mariner transposon. The ratio of whole-genome coverage to mariner Tn coverage in J5-c5 was 4.4, suggesting that there were at least four, and perhaps five, transposon insertions. Reads that could not be aligned strictly within the 33277 reference genome or mariner Tn sequence were assumed to be enriched in junction spanners. These reads were searched for the termini of the mariner Tn, and reads confirmed to be positive for the Tn terminus were subjected to BLAST analysis, from which genomic sequences flanking the insertion could be inferred. The precise insertion sites inferred by this method were verified by amplifying the junction site using PCR and sequencing the PCR product.

**RNA-seq.** RNA was purified from *P. gingivalis* cultures that were treated with TRIzol (Invitrogen) to facilitate cell lysis. Briefly, a fully grown 3-ml culture was spun, the pellet was brought up in 900  $\mu$ l TRIzol and mixed with 200  $\mu$ l chloroform, and the sample was spun for 15 min. The upper aqueous layer was transferred to a new tube, and an equal volume of isopropanol was added, mixed well, and frozen in a -80°C freezer. The next day, the samples were thawed and spun, and the pellet was washed with 70% ethanol and resuspended in water. Twenty micrograms of this sample, comprising crude RNA, was subjected to DNase treatment using RQ1 DNase (Promega). The sample was again subjected to TRIzol and chloroform treatment and spun, and the upper aqueous layer was concentrated using the Clean and Concentrator kit (Zymo Research) according to the manufacturer's instructions. RNA-seq was performed on three independent biological samples of 33277 and J5-c5 RNA using Illumina's HiSeq platform at the University of Washington Center for Precision Diagnostics.

RNA-seq data were analyzed by closely following the guidance outlined by Law et al. (45).

**Construction of *P. gingivalis* 33277 mutants.** Deletion mutations were constructed in *P. gingivalis* 33277 by replacing the gene of interest with either an erythromycin resistance cassette, *ermF*, or a tetracycline resistance cassette, *tetQ*. Flanking sequences of the gene to be deleted, ~500 to 700 bp upstream and 500 to 700 bp downstream, respectively, were amplified by PCR using genomic DNA from *P. gingivalis* 33277 as the template. The primers used for the upstream flanking sequence, a and b, and for the downstream flanking sequence, c and d, are listed in Table 3 for  $\Delta$ PGN\_1123::*erm*, for  $\Delta$ PGN\_1124::*erm* and  $\Delta$ *kgp*::*erm* deletion constructs, and for replacement of Tn1 with *tetQ* in J5-c5. The b and c primers were designed to be overlapping primers that are reverse complements of each other. In general, the forward primer c comprised 15 nucleotides specific to the end of the upstream flanking sequence, an XbaI restriction site, and 15 nucleotides specific to the beginning of the downstream flanking sequence. The upstream and downstream flanking fragments were first amplified separately using a-b and c-d primer sets, respectively. The two products were cleaned and mixed together, and outer primers a-d were used to amplify the aligned product that comprised both flanks. The amplified flanks were ligated by TA cloning into pGEM-T Easy, a narrow-host-range vector that can propagate in *E. coli* but is a suicide vector in *P. gingivalis*. Finally, an *ermF* or *tetQ* cassette was introduced between the flanking sequences into the XbaI site to complete each deletion construct.

*P. gingivalis* 33277 deletion mutants were generated by introducing each deletion plasmid into *P. gingivalis* 33277 by natural transformation. Briefly,  $0.5 \times 10^9$  bacteria were mixed with 1  $\mu$ g of the deletion plasmid, incubated overnight in a loosely fastened screw-cap Eppendorf tube in an anaerobic

**TABLE 3** Primers used in this study

Oligonucleotide	Specificity	Orientation	Sequence <sup>a</sup>
Δ1124-a	PGN_1124 upstream flanking sequence	Forward	AGACTCAATAGCAGATCGACG
Δ1124-b	PGN_1124 upstream flanking sequence	Reverse	TTCATACCGCCCAAGgatCCTGTTGCTGCATA
Δ1124-c	PGN_1124 downstream flanking sequence	Forward	TATGACAGCAACAGgatCCTTGGGCGGTATGAA
Δ1124-d	PGN_1124 downstream flanking sequence	Reverse	GACCCAAACATCCATTCGG
Δ1124-confirm	PGN_1124	Reverse	TTCATACATGGCACGCAT
Δ1123-a	PGN_1123 upstream flanking sequence	Forward	ATGCGTGCCATGTATGAGA
Δ1123-b	PGN_1123 upstream flanking sequence	Reverse	GGACTGTCAAAGGAGgatcCTAAGCACAGCAGG
Δ1123-c	PGN_1123 downstream flanking sequence	Forward	CCTGCTGTGCTTAGgatcCTCCTTTGACAGTCC
Δ1123-d	PGN_1123 downstream flanking sequence	Reverse	CCGTAACCGGGTACGAT
Δ1123-confirm	PGN_1123	Reverse	GACCCAAACATCCATTCGG
Δkgp-a	<i>kgp</i> upstream flanking sequence	Forward	atccatggACGCCGATACCCATACTC
Δkgp-b	<i>kgp</i> upstream flanking sequence	Reverse	CACAAAGTCTCCGAGTggatccATTCAGAGAACCACG
Δkgp-c	<i>kgp</i> downstream flanking sequence	Forward	CGTGTTCTCTGAATggatccACTCGGAGACTTTGTG
Δkgp-d	<i>kgp</i> downstream flanking sequence	Reverse	tatgtgcacAACAGTTGTCCGTCAGC
Δkgp-confirm	<i>kgp</i>	Reverse	AACTTCCTAACTGCTGGCAC
ΔTn1-a	Tn1 upstream flanking sequence	Forward	AAGGCTTGATGCTGAAGACC
ΔTn1-b	Tn1 upstream flanking sequence	Reverse	GTCATTTCTTATAAGAATAggatccTATTTACGTTGCGAGC
ΔTn1-c	Tn1 downstream flanking sequence	Forward	GCTCGCAACGTAATAATAggatccTATTCTTAATAAGAATGAC
ΔTn1-d	Tn1 downstream flanking sequence	Reverse	TCTTTGCCGGCATCTTTGC
1123-start	PGN_1123	Forward	ataggcctATGAGATTCTCGCCATTATTATCG
1123-stop	PGN_1123	Reverse	attctaGAGGAATCCACTCGCAAATATC
SJ59	<i>ermF</i> promoter	Forward	ggaattcgcccgCGATAGCTTCCGCTATTG
SJ60	<i>ermF</i> promoter	Reverse	taggtaccaggcctGTAACCTCTTACAGGTGAATAC

<sup>a</sup>Lowercase indicates bases that add or complete a restriction site.

chamber, and plated the next morning on TYHK agar plates containing the appropriate antibiotic. Putative mutant colonies that arose by homologous recombination, entailing a double-crossover of the flanking regions into the chromosome, were seen 5 to 6 days later. Loss of the targeted gene in the deletion mutant was confirmed by PCR analysis using primers designed to detect the coding sequences (Table 3).

**Expression of PGN\_1123 in trans in *P. gingivalis* and *B. thetaiotaomicron*.** The PGN\_1123 gene was amplified using primers 1123-start and 1123-stop (Table 3) by PCR. The 1.2-kb product was cloned into pGem-T-EZ by TA cloning, generating pSJ831. It was next moved into a pT-COW-based plasmid, which is a broad-host-range vector capable of replicating in both *E. coli* and *Bacteroidetes*. pT-COW carries *tetQ*, conferring tetracycline resistance in *Porphyromonas* and *Bacteroides*. This vector was modified into an expression vector, pSJ46, by removing the *tetC* gene, encoding tetracycline resistance in *E. coli*, and replacing it with the promoter of the *ermF* gene, obtained from the *ermFA* erythromycin resistant cassette, and a multiple-cloning site (MCS) immediately downstream of the promoter. The majority of the *tetC* gene was removed by digesting pT-COW with EagI-HinDIII and replacing it with the *ermF* promoter plus MCS. The *ermF* promoter was first cloned into pSU20 using primers SJ59 and SJ60 (Table 3) on an EcoRI-KpnI fragment and was moved from there on an EagI-HinDIII fragment to the EagI-HinDIII sites of the *tetC*-deficient pT-COW vector. The newly introduced EagI-HinDIII fragment contained both the *ermF* promoter and the multiple-cloning site of pSU20.

We were at first unable to introduce PGN\_1123 under control of the *ermF* promoter in pSJ46. We were, however, successful in cloning the gene in the reverse orientation by digesting PGN\_1123 out of pSJ831 on an SphI-XbaI fragment and introducing it into the same sites of pSJ46, generating the plasmid pSJ836. The PGN\_1123-containing pSJ836 was moved to ΔPGN\_1123 mutants by conjugation. Triparental mating was used to mobilize plasmids from *E. coli* to *P. gingivalis* ΔPGN\_1123 or to *B. thetaiotaomicron* with the help of the broad-host-range conjugative helper plasmid pRK231. Briefly, *E. coli* donor and helper strains were subcultured with no antibiotics and grown to an OD<sub>600</sub> of ~0.5. The recipient ΔPGN\_1123 strain was grown to stationary phase, to an OD<sub>600</sub> of >2.0. Fifty milliliters of recipient was spun and resuspended in 5 ml of TYK medium, of which 750 μl was mixed with 250 μl donor and 250 μl helper *E. coli* strains. The mixture was spun down, and the pellet brought up in 100 μl TYK broth and spotted on a TYHK agar plate. After aerobic incubation overnight at 37°C, the spotted mixture was transferred by swab to 1 ml TYK broth and mixed well by vortexing, and 100 μl of the resuspension was plated on TYHK medium containing 0.5 μg/ml tetracycline and incubated anaerobically. Tetracycline-resistant exconjugants were obtained 4 to 5 days later. We confirmed that PGN\_1123 was expressed from pSJ836 in ΔPGN1123::*erm* mutants by RT-PCR, using purified RNA.

pSJ836 was similarly transferred by triparental mating to *B. thetaiotaomicron*. The method was similar to that with *P. gingivalis* except that *B. thetaiotaomicron* was grown to an OD<sub>600</sub> of ~0.2, and 700 μl was mixed with 150 μl *E. coli* donor and helper strains, also grown to an OD<sub>600</sub> of ~0.2.

**Accession number(s).** RNA-seq data obtained by next-generation sequencing of wild-type strain 33277 and the J5-c5 transposon mutant, performed on three biological replicates, are available in the NCBI GEO database under accession number [GSE122289](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122289).

## ACKNOWLEDGMENTS

We sincerely thank Andrew Goodman for providing the mariner transposon-containing *E. coli* strain SM10λpir(pSAM\_Bt). We are grateful to Gabrielle Juliette Sisco and Anusha Etikala for providing technical support during construction of the transposon mutant library and analysis of the J5-c5 mutant. We also thank the Center for Precision Diagnostics at the University of Washington for advice offered and for conducting RNA-seq on a HiSeq platform.

This study was supported by NIH grant R21DE026344 to S.J. and R.P.D.

We note that Roger W. Kramer's work on analysis of next generation sequencing reads was unconnected to his affiliation with the Institute of Systems Biology.

## REFERENCES

- Darveau RP. 2010. Periodontitis: a polymicrobial disruption of host homeostasis. *Nat Rev Microbiol* 8:481–490. <https://doi.org/10.1038/nrmicro2337>.
- Socransky SS, Haffajee AD. 1994. Evidence of bacterial etiology: a historical perspective. *Periodontol* 2000 5:7–25.
- Rafiei M, Kiani F, Sayehmiri K, Sayehmiri F, Tavirani M, Dousti M, Sheikh A. 2018. Prevalence of anaerobic bacteria (*P. gingivalis*) as major microbial agent in the incidence of periodontal diseases by meta-analysis. *J Dent (Shiraz)* 19:232–242.
- Hajishengallis G, Lamont RJ. 2014. Breaking bad: manipulation of the host response by *Porphyromonas gingivalis*. *Eur J Immunol* 44:328–338. <https://doi.org/10.1002/eji.201344202>.
- Zenobia C, Hajishengallis G. 2015. *Porphyromonas gingivalis* virulence factors involved in subversion of leukocytes and microbial dysbiosis. *Virulence* 6:236–243. <https://doi.org/10.1080/21505594.2014.999567>.
- Darveau RP, Belton CM, Reife RA, Lamont RJ. 1998. Local chemokine paralysis, a novel pathogenic mechanism for *Porphyromonas gingivalis*. *Infect Immun* 66:1660–1665.
- Hasegawa Y, Tribble GD, Baker HV, Mans JJ, Handfield M, Lamont RJ. 2008. Role of *Porphyromonas gingivalis* SerB in gingival epithelial cell cytoskeletal remodeling and cytokine production. *Infect Immun* 76:2420–2427. <https://doi.org/10.1128/IAI.00156-08>.
- Kadowaki T, Takii R, Yamatake K, Kawakubo T, Tsukuba T, Yamamoto K. 2007. A role for gingipains in cellular responses and bacterial survival in *Porphyromonas gingivalis*-infected cells. *Front Biosci* 12:4800–4809.
- Curtis MA, Aduse-Opoku J, Rangarajan M. 2001. Cysteine proteases of *Porphyromonas gingivalis*. *Crit Rev Oral Biol Med* 12:192–216.
- Wang M, Shakhathreh M-AK, James D, Liang S, Nishiyama S-I, Yoshimura F, Demuth DR, Hajishengallis G. 2007. Fimbrial proteins of *Porphyromonas gingivalis* mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. *J Immunol* 179:2349–2358. <https://doi.org/10.4049/jimmunol.179.4.2349>.
- Hajishengallis G, Wang M, Liang S, Shakhathreh MA, James D, Nishiyama S, Yoshimura F, Demuth DR. 2008. Subversion of innate immunity by periodontopathic bacteria via exploitation of complement receptor-3. *Adv Exp Med Biol* 632:203–219.
- Bielecka E, Scavenius C, Kantyka T, Jusko M, Mizgalska D, Szmigielski B, Potempa B, Enghild JJ, Prossnitz ER, Blom AM, Potempa J. 2014. Peptidyl arginine deiminase from *Porphyromonas gingivalis* abolishes anaphylatoxin C5a activity. *J Biol Chem* 289:32481–32487.
- Lasica AM, Ksiazek M, Madej M, Potempa J. 2017. The type IX secretion system (T9SS): highlights and recent insights into its structure and function. *Front Cell Infect Microbiol* 7:215. <https://doi.org/10.3389/fcimb.2017.00215>.
- Darveau RP, Hajishengallis G, Curtis MA. 2012. *Porphyromonas gingivalis* as a potential community activist for disease. *J Dent Res* 91:816–820. <https://doi.org/10.1177/0022034512453589>.
- Hajishengallis G, Darveau RP, Curtis MA. 2012. The keystone-pathogen hypothesis. *Nat Rev Microbiol* 10:717–725. <https://doi.org/10.1038/nrmicro2873>.
- Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskin MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD, Darveau RP, Curtis MA. 2011. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. *Cell Host Microbe* 10:497–506. <https://doi.org/10.1016/j.chom.2011.10.006>.
- Zenobia C, Hasturk H, Nguyen D, Van Dyke TE, Kantarci A, Darveau RP. 2014. *Porphyromonas gingivalis* lipid A phosphatase activity is critical for colonization and increasing the commensal load in the rabbit ligature model. *Infect Immun* 82:650–659. <https://doi.org/10.1128/IAI.01136-13>.
- Ogawa T, Asai Y, Makimura Y, Tamai R. 2007. Chemical structure and immunobiological activity of *Porphyromonas gingivalis* lipid A. *Front Biosci* 12:3795–3812.
- Bainbridge BW, Darveau RP. 2001. *Porphyromonas gingivalis* lipopolysaccharide: an unusual pattern recognition receptor ligand for the innate host defense system. *Acta Odontol Scand* 59:131–138.
- Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282:2085–2088.
- Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. 1999. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J Immunol* 162:3749–3752.
- Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. *J Exp Med* 189:1777–1782.
- Coats SR, Pham TT, Bainbridge BW, Reife RA, Darveau RP. 2005. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize *Escherichia coli* lipopolysaccharide at the TLR4 signaling complex. *J Immunol* 175:4490–4498.
- Medzhitov R, Janeway C, Jr. 2000. The Toll receptor family and microbial recognition. *Trends Microbiol* 8:452–456.
- Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. *Annu Rev Biochem* 71:635–700. <https://doi.org/10.1146/annurev.biochem.71.110601.135414>.
- Jain S, Darveau RP. 2010. Contribution of *Porphyromonas gingivalis* lipopolysaccharide to periodontitis. *Periodontol* 2000 54:53–70. <https://doi.org/10.1111/j.1600-0757.2009.00333.x>.
- Kumada H, Haishima Y, Watanabe K, Hasegawa C, Tsuchiya T, Tanamoto K, Umemoto T. 2008. Biological properties of the native and synthetic lipid A of *Porphyromonas gingivalis* lipopolysaccharide. *Oral Microbiol Immunol* 23:60–69. <https://doi.org/10.1111/j.1399-302X.2007.00392.x>.
- Zhang Y, Gaekwad J, Wolfert MA, Boons GJ. 2008. Synthetic tetra-acylated derivatives of lipid A from *Porphyromonas gingivalis* are antagonists of human TLR4. *Org Biomol Chem* 6:3371–3381. <https://doi.org/10.1039/b809090d>.
- Coats SR, Jones JW, Do CT, Braham PH, Bainbridge BW, To TT, Goodlett DR, Ernst RK, Darveau RP. 2009. Human Toll-like receptor 4 responses to *P. gingivalis* are regulated by lipid A 1- and 4'-phosphatase activities. *Cell Microbiol* 11:1587–1599. <https://doi.org/10.1111/j.1462-5822.2009.01349.x>.
- Al-Qutub MN, Braham PH, Karimi-Naser LM, Liu X, Genco CA, Darveau RP. 2006. Hemin-dependent modulation of the lipid A structure of *Porphyromonas gingivalis* lipopolysaccharide. *Infect Immun* 74:4474–4485. <https://doi.org/10.1128/IAI.01924-05>.
- Reife RA, Coats SR, Al-Qutub M, Dixon DM, Braham PA, Billharz RJ, Howald WN, Darveau RP. 2006. *Porphyromonas gingivalis* lipopolysaccharide lipid A heterogeneity: differential activities of tetra- and penta-acylated lipid A structures on E-selectin expression and TLR4 recogni-



- tion. *Cell Microbiol* 8:857–868. <https://doi.org/10.1111/j.1462-5822.2005.00672.x>.
32. Rangarajan M, Aduse-Opoku J, Hashim A, McPhail G, Luklinska Z, Haurat MF, Feldman MF, Curtis MA. 2017. LptO (PG0027) is required for lipid A 1-phosphatase activity in *Porphyromonas gingivalis* W50. *J Bacteriol* 199:e00751-16. <https://doi.org/10.1128/JB.00751-16>.
  33. Slocum C, Coats SR, Hua N, Kramer C, Papadopoulos G, Weinberg EO, Gudino CV, Hamilton JA, Darveau RP, Genco CA. 2014. Distinct lipid A moieties contribute to pathogen-induced site-specific vascular inflammation. *PLoS Pathog* 10:e1004215. <https://doi.org/10.1371/journal.ppat.1004215>.
  34. Trent MS, Pabich W, Raetz CR, Miller SI. 2001. A PhoP/PhoQ-induced lipase (PagL) that catalyzes 3-O-deacylation of lipid A precursors in membranes of *Salmonella typhimurium*. *J Biol Chem* 276:9083–9092. <https://doi.org/10.1074/jbc.M010730200>.
  35. Reynolds CM, Ribeiro AA, McGrath SC, Cotter RJ, Raetz CRH, Trent MS. 2006. An outer membrane enzyme encoded by *Salmonella typhimurium* lpxR that removes the 3'-acyloxyacyl moiety of lipid A. *J Biol Chem* 281:21974–21987. <https://doi.org/10.1074/jbc.M603527200>.
  36. Geurtsen J, Steeghs L, Hove JT, van der Ley P, Tommassen J. 2005. Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues. *J Biol Chem* 280:8248–8259. <https://doi.org/10.1074/jbc.M414235200>.
  37. Chen Y-Y, Peng B, Yang K, Glew MD, Veith PD, Cross KJ, Goldie KN, Chen D, O'Brien-Simpson N, Dashper SG, Reynolds EC. 2011. The outer membrane protein LptO is essential for the O-deacylation of LPS and the co-ordinated secretion and attachment of A-LPS and CTD proteins in *Porphyromonas gingivalis*. *Mol Microbiol* 79:1380–1401. <https://doi.org/10.1111/j.1365-2958.2010.07530.x>.
  38. Barth K, Remick DG, Genco CA. 2013. Disruption of immune regulation by microbial pathogens and resulting chronic inflammation. *J Cell Physiol* 228:1413–1422. <https://doi.org/10.1002/jcp.24299>.
  39. Palm E, Khalaf H, Bengtsson T. 2013. *Porphyromonas gingivalis* down-regulates the immune response of fibroblasts. *BMC Microbiol* 13:155. <https://doi.org/10.1186/1471-2180-13-155>.
  40. Hajishengallis G. 2011. Immune evasion strategies of *Porphyromonas gingivalis*. *J Oral Biosci* 53:233–240. <https://doi.org/10.2330/joralbiosci.53.233>.
  41. Duncan L, Yoshioka M, Chandad F, Grenier D. 2004. Loss of lipopolysaccharide receptor CD14 from the surface of human macrophage-like cells mediated by *Porphyromonas gingivalis* outer membrane vesicles. *Microb Pathog* 36:319–325. <https://doi.org/10.1016/j.micpath.2004.02.004>.
  42. Sugawara S, Nemoto E, Tada H, Miyake K, Imamura T, Takada H. 2000. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from *Porphyromonas gingivalis* leading to lipopolysaccharide hyporesponsiveness. *J Immunol* 165:411–418.
  43. Goodman AL, McNulty NP, Zhao Y, Leip D, Mitra RD, Lozupone CA, Knight R, Gordon JI. 2009. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe* 6:279–289. <https://doi.org/10.1016/j.chom.2009.08.003>.
  44. Jain S, Coats SR, Chang AM, Darveau RP. 2013. A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by *Porphyromonas gingivalis*. *Infect Immun* 81:1277–1286. <https://doi.org/10.1128/IAI.01036-12>.
  45. Law CW, Alhamdoosh M, Su S, Smyth GK, Ritchie ME. 2016. RNA-seq analysis is easy as 1–2–3 with limma, Glimma and edgeR. *F1000Res* 5:1408. <https://doi.org/10.12688/f1000research.9005.1>.
  46. Rutten L, Geurtsen J, Lambert W, Smolenaers JJM, Bonvin AM, de Haan A, van der Ley P, Egmond MR, Gros P, Tommassen J. 2006. Crystal structure and catalytic mechanism of the LPS 3-O-deacylase PagL from *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 103:7071–7076. <https://doi.org/10.1073/pnas.0509392103>.
  47. Rutten L, Mannie J-PBA, Stead CM, Raetz CRH, Reynolds CM, Bonvin AMJJ, Tommassen JP, Egmond MR, Trent MS, Gros P. 2009. Active-site architecture and catalytic mechanism of the lipid A deacylase LpxR of *Salmonella typhimurium*. *Proc Natl Acad Sci U S A* 106:1960–1964. <https://doi.org/10.1073/pnas.0813064106>.
  48. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2015. The I-TASSER Suite: protein structure and function prediction. *Nat Methods* 12:7–8. <https://doi.org/10.1038/nmeth.3213>.
  49. Walters S, Rodrigues P, Bélanger M, Whitlock J, Progulsk-Fox A. 2009. Analysis of a band 7/MEC-2 family gene of *Porphyromonas gingivalis*. *J Dent Res* 88:34–38. <https://doi.org/10.1177/0022034508328381>.
  50. Song Y-H, Kozarov EV, Walters SM, Cao SL, Handfield M, Hillman JD, Progulsk-Fox A. 2002. Genes of periodontopathogens expressed during human disease. *Ann Periodontol* 7:38–42. <https://doi.org/10.1902/annals.2002.7.1.38>.
  51. Coats SR, Berezow AB, To TT, Jain S, Bainbridge BW, Banani KP, Darveau RP. 2011. The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria. *Infect Immun* 79:203–210. <https://doi.org/10.1128/IAI.00937-10>.
  52. Kawasaki K, Ernst RK, Miller SI. 2004. 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of *Salmonella typhimurium*, modulates signaling through Toll-like receptor 4. *J Biol Chem* 279:20044–20048. <https://doi.org/10.1074/jbc.M401275200>.
  53. Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, Stead CM, Trent MS, Miller SI. 2006. The *Pseudomonas aeruginosa* lipid A deacylase: selection for expression and loss within the cystic fibrosis airway. *J Bacteriol* 188:191–201. <https://doi.org/10.1128/JB.188.1.191-201.2006>.
  54. Kawahara K, Tsukano H, Watanabe H, Lindner B, Matsuura M. 2002. Modification of the structure and activity of lipid A in *Yersinia pestis* lipopolysaccharide by growth temperature. *Infect Immun* 70:4092–4098.
  55. Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. 2004. Variation in lipid A structure in the pathogenic yersiniae. *Mol Microbiol* 52:1363–1373. <https://doi.org/10.1111/j.1365-2958.2004.04059.x>.
  56. Reines M, Llobet E, Dahlström KM, Pérez-Gutiérrez C, Llompard CM, Torrecabota N, Salminen TA, Bengoechea JA. 2012. Deciphering the acylation pattern of *Yersinia enterocolitica* lipid A. *PLoS Pathog* 8:e1002978. <https://doi.org/10.1371/journal.ppat.1002978>.
  57. Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E. 2006. Virulence factors of *Yersinia pestis* are overcome by a strong lipopolysaccharide response. *Nat Immunol* 7:1066–1073. <https://doi.org/10.1038/ni1386>.
  58. Corcoran CP, Podkaminski D, Papenfort K, Urban JH, Hinton JCD, Vogel J. 2012. Superfolder GFP reporters validate diverse new mRNA targets of the classic porin regulator, MicF RNA. *Mol Microbiol* 84:428–445. <https://doi.org/10.1111/j.1365-2958.2012.08031.x>.
  59. Zhang Y-F, Han K, Chandler CE, Tjaden B, Ernst RK, Lory S. 2017. Probing the sRNA regulatory landscape of *P. aeruginosa*: post-transcriptional control of determinants of pathogenicity and antibiotic susceptibility. *Mol Microbiol* 106:919–937. <https://doi.org/10.1111/mmi.13857>.
  60. Ogawa R, Yen H, Kawasaki K, Tobe T. 2018. Activation of lpxR gene through enterohaemorrhagic *Escherichia coli* virulence regulators mediates lipid A modification to attenuate innate immune response. *Cell Microbiol* 20. <https://doi.org/10.1111/cmi.12806>.
  61. Elhenawy W, Bording-Jorgensen M, Valguamera E, Haurat MF, Wine E, Feldman MF. 2016. LPS remodeling triggers formation of outer membrane vesicles in *Salmonella*. *mBio* 7:e00940-16. <https://doi.org/10.1128/mBio.00940-16>.
  62. Gui MJ, Dashper SG, Slakeski N, Chen Y-Y, Reynolds EC. 2016. Spheres of influence: *Porphyromonas gingivalis* outer membrane vesicles. *Mol Oral Microbiol* 31:365–378. <https://doi.org/10.1111/omi.12134>.
  63. Xie H. 2015. Biogenesis and function of *Porphyromonas gingivalis* outer membrane vesicles. *Future Microbiol* 10:1517–1527. <https://doi.org/10.2217/fmb.15.63>.
  64. Schromm AB, Brandenburg K, Loppnow H, Moran AP, Koch MH, Rietchel ET, Seydel U. 2000. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. *Eur J Biochem* 267:2008–2013.
  65. Haurat MF, Aduse-Opoku J, Rangarajan M, Dorobantu L, Gray MR, Curtis MA, Feldman MF. 2011. Selective sorting of cargo proteins into bacterial membrane vesicles. *J Biol Chem* 286:1269–1276.
  66. Veith PD, Chen Y-Y, Gorasia DG, Chen D, Glew MD, O'Brien-Simpson NM, Cecil JD, Holden JA, Reynolds EC. 2014. *Porphyromonas gingivalis* outer membrane vesicles exclusively contain outer membrane and periplasmic proteins and carry a cargo enriched with virulence factors. *J Proteome Res* 13:2420–2432. <https://doi.org/10.1021/pr401227e>.
  67. Gabarrini G, Heida R, van Ieperen N, Curtis MA, van Winkelhoff AJ, van Dijk JM. 2018. Dropping anchor: attachment of peptidylarginine deiminase via A-LPS to secreted outer membrane vesicles of *Porphyromonas gingivalis*. *Sci Rep* 8:8949. <https://doi.org/10.1038/s41598-018-27223-5>.
  68. Gorasia DG, Veith PD, Chen D, Seers CA, Mitchell HA, Chen Y-Y, Glew MD, Dashper SG, Reynolds EC. 2015. *Porphyromonas gingivalis* type IX secretion substrates are cleaved and modified by a sortase-like mecha-

- nism. *PLoS Pathog* 11:e1005152. <https://doi.org/10.1371/journal.ppat.1005152>.
69. Veith PD, Glew MD, Gorasia DG, Reynolds EC. 2017. Type IX secretion: the generation of bacterial cell surface coatings involved in virulence, gliding motility and the degradation of complex biopolymers. *Mol Microbiol* 106:35–53. <https://doi.org/10.1111/mmi.13752>.
70. Haurat MF, Elhenawy W, Feldman MF. 2015. Prokaryotic membrane vesicles: new insights on biogenesis and biological roles. *Biol Chem* 396:95–109. <https://doi.org/10.1515/hsz-2014-0183>.
71. Lappann M, Otto A, Becher D, Vogel U. 2013. Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of *Neisseria meningitidis*. *J Bacteriol* 195:4425–4435. <https://doi.org/10.1128/JB.00625-13>.
72. Sidhu VK, Vorhölter F-J, Niehaus K, Watt SA. 2008. Analysis of outer membrane vesicle associated proteins isolated from the plant pathogenic bacterium *Xanthomonas campestris* pv. *campestris*. *BMC Microbiol* 8:87. <https://doi.org/10.1186/1471-2180-8-87>.
73. Galka F, Wai SN, Kusch H, Engelmann S, Hecker M, Schmeck B, Hippenstiel S, Uhlin BE, Steinert M. 2008. Proteomic characterization of the whole secretome of *Legionella pneumophila* and functional analysis of outer membrane vesicles. *Infect Immun* 76:1825–1836. <https://doi.org/10.1128/IAI.01396-07>.
74. Kato S, Kowashi Y, Demuth DR. 2002. Outer membrane-like vesicles secreted by *Actinobacillus actinomycetemcomitans* are enriched in leukotoxin. *Microb Pathog* 32:1–13. <https://doi.org/10.1006/mpat.2001.0474>.
75. Elhenawy W, Debelyy MO, Feldman MF. 2014. Preferential packing of acidic glycosidases and proteases into *Bacteroides* outer membrane vesicles. *mBio* 5:e00909-14. <https://doi.org/10.1128/mBio.00909-14>.
76. Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F. 2014. Inflammatory caspases are innate immune receptors for intracellular LPS. *Nature* 514:187–192. <https://doi.org/10.1038/nature13683>.
77. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. 2013. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. *Science* 341:1250–1253. <https://doi.org/10.1126/science.1240988>.
78. Klein BA, Tenorio EL, Lazinski DW, Camilli A, Duncan MJ, Hu LT. 2012. Identification of essential genes of the periodontal pathogen *Porphyromonas gingivalis*. *BMC Genomics* 13:578. <https://doi.org/10.1186/1471-2164-13-578>.